FiercePharma on FDA’s Draft Guidance for Social Media Marketing by Pharma Companies
As seen in FiercePharmaMarketing’s “How to Speak on Social Media? Finally, the FDA Offers More Specific Clues”
FiercePharmaMarketing reports that the Food and Drug Administration (FDA) recently issued draft guidance for pharmaceutical companies looking to utilize social media for marketing purposes. The two sets of rules address how the risks-and-benefits disclosures that must be included in all promotional materials should be published on social media that limits the length of such messages, as well as how and when pharmaceutical companies should address misinformation posted by third parties.
According to Kaye Scholer Life Sciences Partner Lori Leskin, "The two different guidance drafts reaffirm the FDA's intent that information about potential risks be included along with the potential benefits, but also recognizes the realities of today's social media platforms." She added, "Up until now, pharmaceutical companies have not engaged with the public on social media, in part due to the uncertainty of the regulatory atmosphere governing their participation."